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ABSTRACT:
BRCA1/p220-assocaited and triple negative/basal-like (TN/BL) tumors are 
aggressive and incurable breast cancer diseases that share among other features 
the no/low BRCA1/p220 expression. Here we show that BRCA1/p220 silencing in 
normal human mammary epithelial (HME) cells reduces expression of two RNA-
destabilizing proteins, namely AUF1 and pCBP2, both proteins bind and destabilize 
BRCA1-IRIS mRNA. BRCA1-IRIS overexpression in HME cells triggers expression of 
several TN/BL markers, e.g., cytokeratins 5 and 17, p-cadherin, EGFR and cyclin E 
as well as expression and activation of the pro-survival proteins; AKT and survivin. 
BRCA1-IRIS silencing in the TN/BL cell line, SUM149 or restoration of BRCA1/p220 
expression in the mutant cell line, HCC1937 reduced expression of TN/BL markers, 
AKT, survivin, and induced cell death. Collectively, we propose that BRCA1/p220 
loss of expression or function triggers BRCA1-IRIS overexpression through a post-
transcriptional mechanism, which in turn promotes formation of aggressive and 
invasive breast tumors by inducing expression of TN/BL and survival proteins.
INTRODUCTION
Women with BRCA1/p220 mutations are predisposed 
to early-onset breast cancer [1,2]. Although triple 
negative/basal-like (TN/BL) are sporadic tumors, they 
share many phenotypical, immunohistochemical, clinical 
and molecular characteristics with BRCA1/p220-mutant 
cancers [3,4]. Loss of BRCA1/p220 tumor suppression 
function often leads to profound increase in genomic 
instability [5,6], likely due to lack in DNA damage 
repair [7], in cell-cycle checkpoints activation [8] or in 
ubiquitylation-mediated degradation of proliferation (e.g., 
estrogen receptor [ER]) or survival (e.g., AKT) proteins 
[9-11]. 
Apoptosis evasion allows further transforming 
mutations to accumulate in cancer cells and increase 
the possibility of disease progression and/or resistance 
to therapy [12,13]. About 50% of breast cancers carry 
dysfunctional p53 [14], and thus fail to arrest the cell 
cycle when damaged becoming chemo-drug resistant 
[14]. Similarly, ~40% of breast cancers show increase 
AKT kinase activity [15] and are apoptosis and chemo-
drug resistant [16,17].
Transcription upregulation, enhanced mRNA 
stabilization or suppression of protein degradation can 
all lead to increase in gene expression [18]. The rate of 
decay of certain mRNAs is regulated by the interaction 
of sequence-specific trans-acting, mRNA destabilizing 
proteins (reviewed in [19]), such as the poly(U)-binding 
factor (aka hnRNPD/AUF1, see [20,21]) and the poly(rC)-
binding proteins (aka hnRNPE/pCBP1-4, see [22]) or 
mRNA stabilizing proteins, such as HuR (aka ELAVL1, 
see [23]) with cis-acting AU- or C-rich elements (ARE) 
in the 3`-UTR of these mRNAs. In human, ~10% of 
the genes mostly oncogenes are regulated by this post-
transcriptional mechanism [24-27]. Not surprisingly, 
several of these destabilizing proteins are downregulated 
in cancers [28,29]. 
BRCA1-IRIS is a recently identified, 1399 residue 
BRCA1/p220 locus proto-oncogene [30] made from the 
first 11 exons and 34-amino acid encoded by BRCA1/
p220 intron 11 (for details see [30]). BRCA1-IRIS 
overexpression inhibits geminin function, thus promoting 
DNA replication [30], triggers cyclin D1 expression, thus 
promoting cell proliferation [31,32] and prevents p53 and/
or p38MAPK activation or enhances AKT and survivin Oncotarget 2012; 3:  299-313 300 www.impactjournals.com/oncotarget
expression/activation, thus increases cell tolerance to cell-/
geno-toxic stimuli [33,34].
Here, we show that BRCA1-IRIS overexpression 
in breast tumor cells is, at least partially, BRCA1/
p220-dependent. BRCA1/p220 silencing in HME cells 
downregulated expression of the RNA destabilizing 
proteins, AUF1 and pCBP2, that bind to BRCA1-
IRIS  mRNA 3`-UTR and destabilize it. BRCA1-IRIS 
overexpression in HME cells triggered expression of the 
TN/BL markers, cytokeratins 5 and 17 (CK5 and 17), 
p-cadherin (CDH3), EGFR and cyclin E [35] as well as 
expression and activation of the survival factors, AKT 
and survivin. BRCA1-IRIS silencing or BRCA1/p220 
overexpression in BRCA1/p220-mutant or TN/BL cancer 
cell lines reduced expression of these TN/BL markers, 
AKT and survivin and induced cell death. Our data show 
that BRCA1/p220 loss of expression or function generates 
aggressive breast cancer cells, in part, by upregulating 
BRCA1-IRIS expression, implying that chemotherapeutic 
targeting of BRCA1-IRIS could be pursued for breast 
cancer patients with BRCA1/p220-associated or TN/BL 
diseases.
RESULTS
BRCA1-IRIS overexpression in BRCA1/p220 
none-/low-expressing breast cancer cells 
We showed earlier an inverse correlation between 
BRCA1-IRIS and BRCA1/p220 expressions in breast 
cancer  cell  lines  [30].  Here,  we  confirmed  that  by 
analyzing proteins and RNAs isolated from several 
exponentially growing breast cancer cell lines and 2 
normal HME cell lines. As expected western blot analysis 
using mouse monoclonal antibodies [30,36] and real 
time RT/qPCR, respectively, showed that in normal 
HME cell lines expressing high levels of BRCA1/p220 
protein (Figure 1A) and mRNA (Figure 1B), BRCA1-IRIS 
protein (Figure 1A) and mRNA (Figure 1B) levels were 
significantly lower. In contrast, in sporadic or BRCA1/
p220-mutant (e.g., HCC1937), low or none BRCA1/p220-
expressing cell lines, respectively (see figure 1A and 1B), 
BRCA1-IRIS mRNA and protein expression significantly 
increased (Figure 1A and 1B).
BRCA1/p220 does not affect BRCA1-IRIS protein 
stability
To understand the underlying molecular mechanism 
behind this inverse relationship, we considered three 
mutually exclusive scenarios. BRCA1/p220 could directly 
or indirectly; a) suppress BRCA1-IRIS gene transcription, 
b) decrease BRCA1-IRIS mRNA stability, or c) trigger 
BRCA1-IRIS protein degradation (BRCA1/p220 forms 
an E3 ligase with BARD1, see [9,10]). To distinguish 
between these possibilities, BRCA1/p220 or BARD1 were 
silenced in HME cells for 72h (see Figure 2A, far right 
panels) and cells were exposed to 10µM of cycloheximide 
(protein synthesis inhibitor) during the last 24h. 
The levels of BRCA1-IRIS and actin proteins were 
measured using western blot on proteins isolated from 
these cells using sonication. All data were normalized 
to actin protein level in siLuc/no cycloheximide treated 
cells, which was taken as 1 (Figure 2A, left). As 
expected BRCA1-IRIS protein level decreased following 
cycloheximide treatment in control-, BARD1- and 
BRCA1/p220-silenced cells (Figure 2A, left). In the 
absence of cycloheximide, however, BRCA1-IRIS protein 
level was higher in BRCA1/p220-silenced cells, compared 
to control and BARD1-silenced cells (Figure 2A, left). 
Moreover, the levels of BRCA1-IRIS and GAPDH mRNAs 
was measured using real-time RT/qPCR on RNAs isolated 
from these cells. All data were normalized to GAPDH 
Figure 1: Expression of BRCA1-IRIS and BRCA1/p220 in breast cancers cell lines. Western blot (A) and RT/PCR (B) 
analysis of BRCA1-IRIS and BRCA1/p220 in immortalized normal HME cell lines (HME1 and HME2), sporadic and one inherited 
(HCC1937) breast cancer cell lines. The RNA levels in (B) are normalized to the levels of GAPDH found in each cell line.Oncotarget 2012; 3:  299-313 301 www.impactjournals.com/oncotarget
mRNA level in siLuc/no cycloheximide treated cells, 
which was taken as 1 (Figure 1A, right). BRCA1-IRIS 
mRNA level increased in control and BARD1-silenced 
cells following cycloheximide treatment only (Figure 
1A, right), whereas in BRCA1/p220-silenced cells before 
and after cycloheximide treatment (Figure 1A, right). 
These data argue against an effect of BRCA1/p220 and/
or BRAD1 on the stability of BRCA1-IRIS protein. In 
fact, previously we were unable to detect any interaction 
between BRCA1-IRIS protein and BRCA1/p220 or 
BARD1 proteins in vitro or in vivo (see [30]).
BRCA1/p220 destabilizes BRCA1-IRIS mRNA 
Next, we studied whether BRCA1/p220 affects 
BRCA1-IRIS mRNA stability (known to be controlled by 
elements in the 3`-UTRs of mRNAs). A BRCA1-IRIS 
cDNA that includes the entire 3`-UTR of BRCA1-IRIS 
(see [30]) was cloned in a doxycycline (Dox) inducible 
Figure 2: BRCA1/p220 silencing triggers BRCA1-IRIS expression in HME cells. (A) Western blot (right) or RT/qPCR 
(left) analysis of the fold induction in BRCA1-IRIS protein normalized to actin or mRNA normalized to GAPDH mRNA, respectively in 
HME cells silenced (for 72h) from control (Luc), BRCA1/p220 and BARD1 and treated or not with cycloheximide during the last 24h. 
Data represent the means ± SD from triplicate, done three independent times, whereas ** is a p≤0.01. Far right panels show the effects of 
BRCA1/p220 (upper panels) and BARD1 (lower panels) siRNA on the expression of their cognate protein in HME cells. RT/qPCR analysis 
(B) or western analysis (C) of BRCA1-IRIS mRNA or protein, respectively in parental, uninducible IRISa and inducible IRISb and IRISc 
HME cell lines following control or BRCA1/p220 silencing for 24, 48, 72 or 168h. Data in (B) represent the means ± SD from triplicate, 
done three independent times, whereas * is a p≤0.05 and ** is a p≤0.01. Right panels in (B) show analysis for BRCA1-IRIS overexpression 
in the different inducible cell lines (upper panels), and the effect of BRCA1/p220 siRNA on the expression of BRCA1/p220 protein at 0, 
72 and 168h (lower panels). Oncotarget 2012; 3:  299-313 302 www.impactjournals.com/oncotarget
mammalian expression vector, infected in HME cells 
and one uninducible (IRISa) and two inducible (IRISb 
and c) clones were selected to study further (Figure 2B, 
right upper panel). We reasoned that since BRCA1-IRIS 
is expressed in these cells from an exogenous promoter, 
they should be a good system to explore whether BRCA1/
p220 affects BRCA1-IRIS expression by a transcriptional 
or post-transcriptional mechanism. Thus parental, IRISa, 
b and c were grown in the absence or presence of Dox 
(2µg/ml), in the presence of Dox but cells were transfected 
with BRCA1-IRIS or BRCA1/p220 siRNAs. RNAs and 
proteins (using sonication) were isolated at 24, 48, 72 
or 168h post-siRNA transfection and the expression of 
BRCA1-IRIS mRNA and protein in each treatment was 
measured using real time RT/PCR (Figure 2B, left) and 
western blot (Figure 2C), respectively.  
In the absence of Dox the 4 cell lines expressed 
normal levels of BRCA1-IRIS mRNA (black lines in 
Figure 2B, left) and protein (Figure 2C). Dox induced 
BRCA1-IRIS mRNA (compare green to black lines in 
Figure 2B, left) and protein (Figure 2C) expression in 
IRISb and c and not parental or IRISa starting at 24h. 
BRCA1-IRIS silencing decreased BRCA1-IRIS mRNA 
(see red lines in Figure 2B, left) and protein (Figure 2C) 
in all cell lines (although less pronounced in induced 
IRISb and IRISc). The expression returned to pre-siRNA 
transfection levels at 168h (see red lines in Figure 2B, left 
and 2C). BRCA1/p220 silencing (Figure 2B, right lower 
panels), however, increased BRCA1-IRIS mRNA (blue 
lines in Figure 2B, left) and protein (Figure 2C) levels in 
all cell lines starting at 24h. These effects also disappeared 
at 168h post-siRNA transfection (blue lines in Figure 2B, 
Figure 3: BRCA1/p220 controls BRCA1-IRIS mRNA stability. (A) Expression of the indicated proteins in BRCA1/p220-
silenced HME, MCF7 and MDAMB231 cells (left) or BRCA1/p220 overexpressing MDAMB468 and SKBR3 cells (right). (B) Expression 
of BRCA1-IRIS mRNA in BRCA1/p220-silenced HME, MCF7 and MDAMB231 cells (left) or BRCA1/p220 overexpressing MDAMB468 
and SKBR3 cells (right). (C) Expression of the indicated proteins in BRCA1/p220-, AUF1-, pCBP2- or HuR-silenced HME cells (upper 
panel) and the expression of BRCA1-IRIS in these cells (lower panels). (D) Expression of the indicated proteins (72h, left) or BRCA1-
IRIS mRNA (at 25 PCR cycle, at 72h) in control-, AUF1-, or pCBP2-silenced MCF7 or MDAMB231 cells. Stability (t1/2) of GAPDH 
(E) or BRCA1-IRIS (F) mRNAs as detected using real-time RT-qPCR analysis in BRCA1/p220-, AUF1-, pCBP2- or HuR-silenced HME 
cells treated with Actinomycin D (Act D) during the last 10h. Data are normalized to the levels of 18S rRNA in each experiment and are 
represented as a percentage of the mRNA levels measured at time 0 (before Act D addition) or 2, 4, 6, 8 and 10h after Act D addition using a 
semi-logarithmic scale. Data are presented as the means ± SD from triplicates, done three independent times (in all cases p≤0.001 compared 
to sicontrol cells). Oncotarget 2012; 3:  299-313 303 www.impactjournals.com/oncotarget
Figure 4: Identification and analysis of AREs motifs in BRCA1-IRIS 3`-UTR region. (A) The 3`-UTR region of BRCA1-
IRIS (i.e. part of BRCA1/p220 intron 11) where putative AUF-1 (red sequences) and pCBP2 (green sequences) binding sites are shown. 
(B) Plasmids carrying BRCA1-IRIS or c-fos 3`UTRs downstream of the luciferase gene in RSV-plasmid were transfecetd in HME with 
siGFP, siBRCA1/p220, siAUF1, sipCBP2 or siHuR and the luciferase activity expressed from these different plasmids was measured using 
luminometer. Data are represented as means ± SD from triplicates done three independent times (in all cases p≤0.01 compared to RSV-Luc 
alone). (C) Representative PCR analyses of the binding of BRCA1-IRIS mRNA to AUF1, pCBP2, HuR in untreated HME cells cytoplamsic 
proteins (polysomes), while binding only to HuR in BRCA1/p220-silenced HME cells. (D) Immunoprecipitation of the indicated proteins 
in BRCA1/p220-silenced HME cells (left), or from BRCA1/p220-reconstituted HCC1937 cells (right). (E) Immunoprecipitated mRNP-
protein complex as percentage of input using AUF1, pCBP2, HuR and BRCA1/p220 antibodies and IgG from cells transfected with control 
or BRCA1/p220 siRNA. (F) Representative PCR analyses of the binding of AUF1 and pCBP2 to BRCA1-IRIS mRNA in BRCA1/p220-
silenced HME cells (upper) or BRCA1/p220-overexpressing HCC1937 (lower) cytoplasmic proteins (polysomes).  Oncotarget 2012; 3:  299-313 304 www.impactjournals.com/oncotarget
left and 2C) when the effect of BRCA1/p220 siRNA 
disappeared (see Figure 2B, right lower panels). 
To ascertain that these effects are dependent on 
the 3`-UTR of BRCA1-IRIS mRNA and not an artifact 
from the plasmid 5`-UTR (known inducer of mRNA 
translation), BRCA1-IRIS + 3`-UTR cDNA was cloned 
into several other mammalian expression vectors. 
Transient transfection of any of the plasmids into HME 
cells with BRCA1/p220 siRNA led to stabilization of the 
BRCA1-IRIS mRNA (not shown). We thus concluded that 
BRCA1/p220 loss stabilizes BRCA1-IRIS mRNA through 
an effect on its 3`-UTR.
Identification  of  BRCA1/p220  induced  trans-
acting proteins that de-stabilize BRCA1-IRIS 
mRNA
In an attempt to identify whether BRCA1/p220 
has an effect on mRNA stability, we searched recently 
performed gene expression microarray data comparing 
BRCA1/p220-expressing to BRCA1/p220-silenced HME 
cells for 3`-UTR binding and destabilizing proteins. Using 
this approach we found that the expressions of the mRNA 
3`-ITR binding and destabilizing proteins, AUF-1 and 
pCBP2 (see introduction) were significantly decreased in 
BRCA1/p220-silenced HME cells (data not shown).
To confirm that, we silenced BRCA1/p220 for 24-
168h in normal HME cells, MCF7 (estrogen receptor-
positive, ER+) or MDAMB231 (ER-) breast cancer cell 
lines (both express detectable levels of BRCA1/p220 
protein, see Figure 1A and 3A, left). We also transiently 
overexpressed (for 24-168h) BRCA1/p220 in two none-/
low-BRCA1/p220 expressing breast cancer cell lines, 
MDAMB468 (TN/BL) and SKBR3 (Her2+) (see Figure 
1A). 
Compared to control treated cells, BRCA1/p220 
silencing (72h) significantly reduced AUF1 and pCBP2 but 
not HuR protein levels in HME, MCF7 and MDAMB231 
cells, and its overexpression (48h) in MDAMB468 and 
SKBR3 cells significantly enhanced AUF1 and pCBP2 but 
not HuR protein levels (see Figure 3A, right). In contrast, 
BRCA1/p220-silencing increased the level of BRCA1-
IRIS protein in HME, MCF7 and MDAMB231 to different 
degrees (see Figure 3A, left), whereas its overexpression 
significantly decreased BRCA1-IRIS protein expression 
in MDAMB468 and SKBR3 cells (Figure 3A, right). 
This was also confirmed at the mRNA level. Indeed in 
real-time RT/PCR and after normalization to the level of 
GAPDH mRNA in each cell line, we found that BRCA1/
p220 silencing increased BRCA1-IRIS mRNA in HME, 
MCF7 and MDAMB231 cells starting at 24h (Figure 
3B, left) until 72h, but returned to control levels at 168h 
(Figure 3B, left). BRCA1/p220 overexpression, on the 
other hand, decreased the level of BRCA1-IRIS mRNA 
in MDAMB468 and SKBR3 cells starting at 24h and 
thereafter (Figure 3B, right). 
To directly assess the effect of AUF1 and pCBP2 on 
BRCA1-IRIS expression, they and BRCA1/p220 were 
separately silenced in HME cells (72h, Figure 3C, upper 
panels), MCF7 or MDAMB231 (72h, Figure 3D, left). 
AUF1 or pCBP2 and not HuR (control) silencing like 
BRCA1/p220 silencing significantly increased the level of 
BRCA1-IRIS protein in HME (Figure 3C, lower panels), 
MCF7 and MDAMB231 (Figure 3D, left) cells. Moreover, 
AUF1- or pCBP2-silencing increased BRCA1-IRIS mRNA 
levels in MCF7 and MDAMB231 cells (shown at 25 PCR 
cycle at 72h, Figure 3D, right). These data confirm that 
expression of BRCA1-IRIS in normal and cancer cell 
lines is, at least partially, BRCA1/p220/AUF1 and pCBP2-
dependent. 
BRCA1/p220 effect on BRCA1-IRIS is post-
transcriptional and not transcriptional
To rule out any effect of BRCA1/p220 on BRCA1-
IRIS gene transcription and to directly assess the effect of 
BRCA1/p220, AUF1 or pCBP2 on BRCA1-IRIS mRNA 
stability, BRCA1-IRIS mRNA half-life (t1/2) was analyzed 
in control-, BRCA1/p220-, AUF1-, pCBP2- or HuR-
silenced (72h) HME cells following exposure to the de 
novo transcription inhibitor actinomycin D (Act D) during 
the last 10h. Total RNAs were collected at 2, 4, 6, 8 and 
10h after Act D treatment and analyzed by real-time RT/
qPCR for BRCA1-IRIS and GAPDH expression.
After normalization to the level of 18S rRNA, the 
none-target and stable GAPDH mRNA level remained 
unchanged following all siRNA transfections (Figure 3E). 
BRCA1-IRIS mRNA t1/2, on the other hand, was 2.5-3h in 
control and HuR-silenced cells (Figure 3F), increased to 
>10h in BRCA1/p220-silenced (Figure 3F) and to >6h 
in AUF1- or pCBP2-silenced HME cells (Figure 3F). 
These data demonstrate that BRCA1/p220 does not affect 
BRCA1-IRIS gene transcription, but instead destabilizes 
BRCA1-IRIS mRNA. 
Identification of destabilizing cis-acting elements 
in BRCA1-IRIS mRNA 3`-UTR
Indeed,  in silico search of BRCA1-IRIS 3`-UTR 
showed the presence of several cis-acting putative ARE 
consensus binding elements for AUF1 (class II AU rich 
binding motifs, see red in Figure 4A) and for pCBP2 
(C-rich binding motifs, see green in Figure 4A), suggesting 
that the 3`-UTR destabilizes BRCA1-IRIS mRNA, in vivo. 
To experimentally confirm that, the entire BRCA1-IRIS 
3`-UTR was cloned downstream of the luciferase coding 
region in the RSV-Luc plasmid (see atop of Figure 4B). 
The 3`-UTR of c-fos (known ARE containing) was also Oncotarget 2012; 3:  299-313 305 www.impactjournals.com/oncotarget
cloned downstream of the luciferase coding region in the 
same plasmid to be used as positive control. Backbone 
plasmid transfection in HME cells produced high-level 
basal luciferase expression (Figure 4B). Introducing 
BRCA1-IRIS or c-fos 3`-UTR downstream of the luciferase 
gene in this plasmid abolished that expression when co-
transfected in HME cells with siGFP and siHuR (negative 
controls, Figure 4B), but not when co-transfected with 
BRCA1/p220, AUF1 or pCBP2 siRNA (Figure 4B). 
Taken together these data suggest that like c-fos 3`-UTR, 
BRCA1-IRIS 3`-UTR carry AUF1 and pCBP2 binding and 
mRNA destabilizing motif(s).
To measure endogenous association between these 
trans-acting factors and the cis-acting elements in BRCA1-
IRIS 3`-UTR, cytoplasmic proteins (polysomes) were 
collected 72h after control- or BRCA1/p220-silencing in 
HME cells in conditions that maintain RNA stability and 
were processed for immunoprecipitation with BRCA1/
p220, AUF1, pCBP2, HuR or IgG (negative control) 
antibodies. All immunoprecipitated samples were DNaseI 
digested to ensure they were free from any genomic 
contaminations before they were RT/PCR interrogated 
for BRCA1-IRIS mRNA. GAPDH mRNA (none target) 
was not immunoprecipitated by any antibody (Figure 4C), 
Figure 5: The effect of BRCA1-IRIS and BRCA1/p220 on the expression of several TN/BL markers. Expression of 
the indicated TN/BL markers mRNAs (left) or proteins (right) in BRCA1/p220-silenced or BRCA1/p220 and BRCA1-IRIS co-silenced 
HME cells (A), BRCA1-IRIS-silenced SUM149 cells (B), BRCA1/p220 overexpressing or BRCA1-IRIS silenced HCC1937 cells (C). 
(D) PCR analysis showing promoters (left) or 10kb upstream regions (right) of CK5, CK17, CDH3, EGFR, cyclin E, AUF1 and pCBP2 
in BRCA1-IRIS or BRCA1/p220 immunoprecipitation from cross-linked HME cells using mono-specific antibodies. (E) ChIP analysis of 
the promoters of the indicated TN/BL markers in control- or c-Jun-silenced MDAMB231 cells or control- or Oct1-silenced HME cells. (F) 
Analysis of the indicated promoters activation in HME cells (left) or MDAMB231 (right) depleted from BRCA1/p220, Oct1, BRCA1-IRIS 
or c-Jun. Inset is the effect of each siRNA on its cognate protein in HME cells.Oncotarget 2012; 3:  299-313 306 www.impactjournals.com/oncotarget
and no PCR amplification was detected when no reverse 
transcriptase (RT) was added to the reactions (Figure 4C). 
In siLuc-transfected cells, AUF1, pCBP2, HuR and not 
IgG or BRCA1/p220 antibodies co-immunoprecipitate 
BRCA1-IRIS mRNA (Figure 4C). This association was 
abolished when BRCA1/p220 was silenced (Figure 4C). 
Finally,  to  confirm  that  these  antibodies 
immunoprecipitate their cognate proteins, HME cells were 
transfected with BRCA1/p220 siRNA or the BRCA1/p220 
mutant cell line; HCC1937 was infected with wild type 
BRCA1/p220 expressing virus. Sp1 (negative control) 
antibody immunoprecipitated similar amounts of Sp1 from 
control and BRCA1/p220-silenced HME cells (Figure 4D, 
left) as well as vector and BRCA1/p220 infected HCC1937 
cells (Figure 4D, right). Higher AUF1 and pCBP2 were 
immunoprecipitated from control- than BRCA1/p220-
silenced HME cells (Figure 4D, left), and increased 
amount of BRCA1-IRIS was immunoprecipitated from 
BRCA1/p220- compared to control-silenced HME cells 
(Figure 4D, left). Furthermore, BRCA1/p220, AUF1 
and pCBP2 were immunoprecipitated from BRCA1/
p220- and not vector-infected HCC1937 cells (Figure 
4D, right) and increased amount of BRCA1-IRIS was 
immunoprecipitated from vector- compared to BRCA1/
p220-infected HCC1937 cells (Figure 4D, right). 
The amounts of BRCA1-IRIS mRNA 
immunoprecipitated from control or BRCA1/p220 silenced 
HME cells by IgG, AUF1, pCBP2, HuR and BRCA1/p220 
antibodies were compared to the total BRCA1-IRIS mRNA 
in polysome extracts using RT/qPCR. While equal amount 
of  BRCA1-IRIS mRNA was immunoprecipitated with 
AUF1, pCBP2 and HuR antibodies from control treated 
cells (~30-35% of total BRCA1-IRIS polysomic mRNA 
see siLuc in Figure 4E), the amount immunoprecipitated 
by AUF1 and pCBP2 dropped to <10%, while the 
amount immunoprecipitated by HuR antibody increased 
to ~50% in BRCA1/p220-silenced cells (Figure 4E). In 
line with that, from polysome extracts, Sp1 antibody 
immunoprecipitated no BRCA1-IRIS mRNA from 
controls, BRCA1/p220-silenced HME cells or BRCA1/
p220-overexpressing HCC1937 cells (Figure 4F). 
BRCA1/p220 silencing in HME cells decreased, whereas 
BRCA1/p220 overexpression in HCC1937 cells increased 
the level of BRCA1-IRIS mRNA immunoprecipitated by 
AUF1 or pCBP2 antibody (Figure 4F). These data show 
that BRCA1-IRIS mRNA is a target for the mRNA de/
stabilizing factors AUF1, pCBP2 and HuR in normal and 
breast cancer cells, and that AUF1, pCBP2 and not HuR 
expression is BRCA1/p220-dependent in these cells. 
Loss of BRCA1/p220 enhances TN/BL phenotype 
via BRCA1-IRIS overexpression 
The fact that BRCA1/p220-associated and TN/
BL breast cancers commonly show early onset and 
aggressive diseases expressing no-/low-BRCA1/p220, 
made us wonder whether BRCA1/p220 loss enhances 
the TN/BL phenotype via upregulating BRCA1-IRIS. 
To test this hypothesis, BRCA1/p220 was silenced in 
the BRCA1/p220-high-/BRCA1-IRIS-low expressing 
HME cells (Figure 5A, upper panels). Total RNAs and 
proteins collected from these cells were then probed for 
the expression of the TN/BL markers, CK5, CK17, CDH3, 
EGFR and cyclin E [35]. As expected, BRCA1/p220 
silencing upregulated the expression of the mRNAs and 
proteins of these markers (which otherwise expressed at 
low levels in HME cells, see Figure 5A, lower panels). 
More importantly, BRCA1-IRIS co-silencing in these 
cells decreased the expression of these markers (Figure 
5A, lower panels). 
Furthermore, BRCA1-IRIS silencing in the TN/BL 
cell line, SUM149 that expresses high levels of BRCA1-
IRIS, CK5, CK17, CDH3, EGFR, cyclin E but no BRCA1/
p220 (Figure 5B) significantly decreased the expression 
of these TN/BL markers mRNAs and proteins (Figure 
5B). Whereas, HCC1937, the BRCA1/p220 mutant cell 
line that expresses high levels of BRCA1-IRIS and TN/
BL markers, but no wild type BRCA1/p220 (Figure 5C), 
reconstitution with full-length BRCA1/p220 cDNA or 
silencing BRCA1-IRIS in them (Figure 5C) decreased the 
levels of TN/BL markers and BRCA1-IRIS mRNA and 
protein (Figure 5C). These data establish that BRCA1/
p220 loss of expression or function enhances the TN/BL 
phenotype in breast cancer cells via upregulating BRCA1-
IRIS expression. 
BRCA1/p220 binds AUF1 and pCBP2 promoters 
while BRCA1-IRIS binds CK5, CK17, CDH3, 
EGFR and cyclin E promoters 
Next, we asked whether these effects are 
transcriptional. In chromatin immunoprecipitation 
(ChIP) experiments, exponentially growing HME cells 
were cross-linked, sonicated (to generate ~500bp DNA 
fragments), then extracts were immunoprecipitated with 
IgG (negative control), BRCA1-IRIS or BRCA1/p220 
monoclonal antibodies. After Immunoprecipitation, cross-
linking was reversed and PCR was used to search for 
specific DNA fragments immunoprecipitated with these 
antibodies. BRCA1-IRIS co-immunoprecipitated CK5, 
CK17, CDH3 and EGFR promoter fragments (Figure 
5D, left), whereas BRCA1/p220 co-immunoprecipitated 
AUF1 and pCBP2 promoter fragments (Figure 5D, 
left). All promoters were present in the input of each 
experiment (Figure 5D, left), and while inputs also 
contained the fragments located ~10kb upstream of each 
promoter (Figure 5D, right), these fragments were not 
co-immunoprecipitated by BRCA1-IRIS or BRCA1/
p220 (Figure 5D, right) antibodies. These data show that 
BRCA1/p220 binds AUF1 and pCBP2, while BRCA1-Oncotarget 2012; 3:  299-313 307 www.impactjournals.com/oncotarget
IRIS binds the promoters of several TN/BL markers. 
Potential transcriptional links necessary for 
BRCA1/p220 or BRCA1-IRIS
Using in silico analysis we compared AUF1 and 
pCBP2 (~1000bp upstream of +1 position) promoters in 
search for common factors that could link BRCA1/p220 
to these genes transcription. An Oct1 binding site was 
common between AUF1 and pCBP2 promoters, which 
is interesting, since BRCA1/p220 was shown recently to 
induce transcription of several genes, including GADD45 
through binding to Oct1 [37]. Also using in silico analysis 
we compared the promoter regions of these TN/BL 
genes (~1000bp upstream of +1 position) for common 
transcription binding sites, and found that all but cyclin 
E share an AP1 binding site. Importantly, we recently 
showed that BRCA1-IRIS induces cyclin D1 expression 
through binding to c-Jun/AP1 [32]. 
To study that, c-Jun was silenced in the BRCA1-
IRIS-overexpressing MDAMB231 cell line (72h, 
Figure 5E, left upper panels) and Oct1 was silenced 
in the BRCA1/p220-expression HME cell line (72h, 
Figure 5E, right upper panels). ChIP analysis of extracts 
isolated from these cells confirmed that c-Jun-silencing 
in MDAMB231 cells significantly reduced the amounts 
of CK5, CK17, CH3 and EGFR promoter fragments co-
immunoprecipitated by BRCA1-IRIS antibody (Figure 
5E, left lower panels), and Oct1-silencing in HME cells, 
dramatically reduced the amount of AUF1 and pCBP2 
promoter fragments co-immunoprecipitate by BRCA1/
p220 antibody (Figure 5E, right lower panels). 
To ascertain these relationships further, CK5, 
EGFR, AUF1, pCBP2 promoters were cloned upstream 
of the luciferase gene in the pGL3 reporter plasmid. Three 
Sp1 binding sites cloned upstream of the luciferase gene 
in this reporter plasmid was used as negative control. 
Positive controls for BRCA1-IRIS transcription activity 
was cyclin D1 promoter driving luciferase reporter (see 
[31]), and for BRCA1/p220 induced transcription activity 
was GADD45 driven luciferase reporter (see [37]). The 
pGL3-AUF1, -pCBP2 and -GADD45, -CK5, -EGFR 
and -CycD1 constructs were co-transfected with GFP-, 
BRCA1/p220-, Oct1-, BRCA1-IRIS- or c-Jun-silenced 
HME (inset in Figure 5F) or MDAMB231 (not shown) 
cells, respectively. Luciferase activity from each reporter 
following the different treatments was measured in each 
case 72h later.
As expected Oct1 silencing significantly decreased 
luciferase expression from GADD45, AUF1 and 
pCBP2 promoters (Figure 5F, left), but had no effect on 
CK5, EGFR or cyclin D1 promoters (Figure 5F, right). 
Importantly,  BRCA1/p220  silencing  also  significantly 
suppressed luciferase expression from GADD45, AUF1 
and pCBP2 promoters (Figure 5F, left), and as expected 
since BRCA1/p220 silencing upregulates BRCA1-IRIS 
expression, a slightly increased in luciferase expression 
from CK5, EGFR and cyclin D1 promoters was measured 
in these cells (Figure 5F, right). On the other hand, c-Jun 
silencing suppressed luciferase expression from cyclin D1, 
CK5 and EGFR promoters (Figure 5F, right) and more 
importantly,  BRCA1-IRIS  silencing  also  significantly 
reduced luciferase expression from these promoters 
(Figure 5F, right). Luciferase expression from AUF1, 
pCBP2 and GADD45 promoters was not affected by c-Jun 
or BRCA1-IRIS silencing (Figure 5F, left). These data 
show that BRCA1/p220 induces expression of AUF1 and 
pCBP2 through binding to and activating Oct1 on their 
promoters, whereas BRCA1-IRIS enhances expression of 
this subset of TN/BL genes by binding to and activating 
c-Jun on their promoters.
Loss of BRCA1/p220 enhances tumor cell survival 
via BRCA1-IRIS overexpression
Next, we studied whether BRCA1-IRIS 
overexpression in no/low BRCA1/p220 expressing 
cells promotes their survival and hence drug resistance 
phenotype associated with TN/BL breast cancers. BRCA1-
IRIS and BRCA1/p220 were separately or together 
silenced or BRCA1-IRIS was overexpressed alone or 
in BRCA1/p220-silenced (i.e. BRCA1/p220 silenced in 
induced IRISb cells) in HME cells. Sonicated proteins 
were analyzed for expression and activation of AKT 
and its down-stream targets survivin and BAD 72h later 
[38,39].
Control treated HME cells express high levels 
of BRCA1/p220, AKT, survivin (Figure 6A) and low 
levels of BRCA1-IRIS, phosphorylated (on T308/
S473)/activated AKT (hereafter p-AKT, Figure 6A) and 
phosphorylated (on S112/136)/inactivated BAD (hereafter 
p-BAD, Figure 6A). BRCA1-IRIS silencing had no effect 
on BRCA1/p220 expression (Figure 6A), dramatically 
decreased AKT, and survivin expression (Figure 6A, 
also [34]) and led to significant decrease in HME and 
HCC1937 cells viability as measured using MTT and 
activated caspase3/7, respectively (Figure 6C and D). 
BRCA1/p220 and BRCA1-IRIS co-silenced cells showed 
similar phenotypes to BRCA1-IRIS only silenced cells 
(Figure 6A-D).
Conversely, BRCA1/p220 silencing upregulated 
expression of BRCA1-IRIS, AKT, p-AKT, survivin and 
p-Bad (Figure 6A), which led to a slight but significant 
increase in viability and decrease in caspase3/7 activation 
(Figure 6C). BRCA1-IRIS overexpression (i.e. induced 
IRISb cells) had no effect on BRCA1/p220 expression, 
dramatically increased AKT, p-AKT, survivin (Figure 
6B, also see [34]) and p-BAD expression (Figure 6B) and 
significantly increased HME and HCC1937 cells viability 
(Figure 6C and D). Indeed, BRCA1/p220 silencing in Oncotarget 2012; 3:  299-313 308 www.impactjournals.com/oncotarget
induced  IRISb  cells  (which  significantly  increased 
BRCA1-IRIS, AKT, p-AKT, survivin and p-BAD 
levels, Figure 6B) or BRCA1-IRIS overexpression in 
HCC1937 dramatically reduced the level of activated 
caspase 3/7, which led to increase in cell number in 
both cell lines above control treated cells (Figure 6C 
and D). Importantly, overexpressing of wild type or 
clinically relevant BRCA1/p220 mutant in HCC1937 
could not overcome the inhibitory effect observed with 
BRCA1-IRIS silencing (Figure 6D). 
Finally, colony assay was used to assess 
the transformation capabilities of BRCA1-IRIS 
overexpression or BRCA1/p220 silencing. HME 
cells were transfected with control or BRCA1-IRIS-
expressing vector, HCC1937 cells were transfected 
with control or BRCA1/p220-expressing vector, and 
MDAMB468 cells were transfected with appropriate 
control, BRCA1-IRIS siRNA or BRCA1/p220-
expressing vector. All cell lines were grown in soft 
agar for 2 weeks, at which time formed colonies were 
stained and counted. Compared to control treated 
cells, BRCA1-IRIS overexpression increased the 
number of HME colonies (Figure 6E, left), BRCA1/
p220 overexpression reduced the number of HCC1937 
colonies (Figure 6E, middle) and BRCA1-IRIS 
silencing or BRCA1/p220 overexpression reduced 
MDAMB468 colonies (Figure 6E, right). These data 
show that BRCA1-IRIS overexpression, like BRCA1/
p220 dowregulation initiates and/or maintains the 
transformation of mammary cells. 
DISCUSSION
BRCA1-IRIS is a novel BRCA1/p220 locus 
produced oncogene. BRCA1/p220 inhibition or 
BRCA1-IRIS overexpression in mammary epithelial 
cells enhances expression of cyclin D1, AKT and 
several other proliferation and survival proteins [31-
Figure 6: The effects of BRCA1-IRIS and/or BRCA1/p220 on the expression and activation of survival proteins, cell 
survival and transformation. Expression or activation of the indicated proteins in control, BRCA1-IRIS, BRCA1/p220 silenced (A), 
BRCA1-IRIS overexpressing or BRCA1-IRIS overexpressing and BRCA1/p220-silenced (B) HME cells. (C) Percentage of viable (MTT 
assay analysis) or dying (caspase 3/7 assay analysis) cells, respectively in HME cells treated as in A and B. Data are presented as means ± 
SD from triplicate, done three independent times, whereas ** is a p≤0.01. (D) Analysis of viability detected using MTT assay and cell death 
detected using caspase 3/7 assays in BRCA1-IRIS-silenced and/or wild type or clinically relevant mutant BRCA1/p220 overexpressing 
HCC1937 cells. Data are presented as the means ± SD from triplicate, done three independent times, whereas ** is a p≤0.01. (E) Soft agar 
analysis of control or BRCA1-IRIS overexpressing HME cells (left), control or BRCA1/p220 overexpressing HCC1937 cells (middle), or 
control, BRCA1-IRIS-silenced or BRCA1/p22Oncotarget 2012; 3:  299-313 309 www.impactjournals.com/oncotarget
34,40,41, and this study]. BRCA1/p220 loss [42] or 
BRCA1-IRIS overexpression (ElShamy, unpublished) 
confers tamoxifen resistance in mammary epithelial 
cells. These observations support the view that BRCA1-
IRIS overexpressing cells are phenotypically equivalent 
to no/low BRCA1/p220 expressing cells. In this study 
we presented a mechanistical support for this notion. We 
showed that, at least partially, BRCA1/p220 loss increases 
BRCA1-IRIS expression by a post-transcriptional 
mechanism, explaining the inverse relationship between 
the two genes.
Human and rat BRCA1/p220 mRNA 3`-UTR 
(~1.5kb) contains several HuR binding sites [43]. The 
BRCA1-IRIS 3`-UTR (~300bp from intron 11), on the 
other hand contains binding sites for pCBP2 [22], AUF1 
and HuR [21]. It is possible that HuR stabilizes both 
mRNAs, and that we fail to detect an effect of HuR on 
BRCA1-IRIS mRNA in HME cells is because the effect 
is perhaps masked by the fact that these cells are BRCA1/
p220 proficient and hence express high levels of AUF1, 
that binds the same sites as HuR [21]. When BRCA1/p220 
expression and/or function are lost and AUF1 expression 
is dropped (e.g., in cancer cells), BRCA1-IRIS mRNA is 
perhaps stabilized by HuR. 
In fact, we recently performed immunohistochemical 
analysis of breast cancer tissue microarray (containing 
>300 aggressive breast cancer tumor samples) and 
discovered that compared to normal tissue, BRCA1-
IRIS is overexpressed in the majority of these tumors, 
that expressed very low levels of AUF1 and pCBP2, 
high levels of cytoplasmic HuR and no BRCA1/p220 
(ElShamy WM, unpublished data). Cytoplasmic HuR was 
proposed recently to be an independent prognostic factor 
for familial breast cancers and a poor prognosis factor for 
sporadic and familial breast cancers, or could even be a 
contributing factor to the disease [44,45]. In fact, in our 
recent publication [33] we showed a strong correlation 
between BRCA1-IRIS overexpression and cytoplasmic 
localization of HuR, in vitro [33]. 
pCBP2 binds to and activates BRCA1/p220 
promoter [46]. It is possible that a positive feedback 
mechanism between BRCA1/p220 and pCBP2 exists, 
which is broken in BRCA1/p220-mutant or TN/BL cells. 
Further studies to elucidate the role of posttranscriptional 
mechanisms controlling BRCA1/p220 and BRCA1-IRIS 
mRNA expression in normal and breast cancer cells are 
required to elucidate the mechanism(s) underlying the 
development of familial and TN/BL breast cancers. 
The inverse relationship we propose here between 
expression of BRCA1/p220 and BRCA1-IRIS seems 
not to be complete. For instance, although MCF7 and 
MDAMB231 cell lines express high levels of BRCA1-
IRIS, both cell lines still express detectable levels of 
BRCA1/p220 (see above). It is possible that while 
intriguing, this mechanism is perhaps not the only 
mechanism involved. In this regard, we recently found 
that BRCA1-IRIS was overexpressed in xenograft 
or orthotopic tumors generated using HME cells 
overexpressing TERT/LT/RasV12 [47]. Oncogenic Ras 
is known to suppress expression of several transcription 
factors, including vitamin D during mammary epithelial 
cell transformation [48]. It is possible that vitamin D is a 
transcription suppressor of BRCA1-IRIS. However, this 
remains only a hypothesis until the promoter of BRCA1-
IRIS has been cloned.
Alternatively, oncogenic Ras overexpression was 
shown recently to decrease the expression of AUF1 
during mammary cell transformation [49]. It is possible 
that in BRCA1/p220 expressing breast cancer tumor cells, 
RasV12 instead stabilizes BRCA1-IRIS mRNA leading 
to its protein overexpression. However, what was even 
more surprising is the fact that tumors generated using 
HME cells overexpressing TERT/LT/BRCA1-IRIS 
were BRCA1/p220-negative [47]. If true also in human 
tumors, this suggests that BRCA1/p220 loss of expression 
increases BRCA1-IRIS, which in a negative feedback 
mechanism suppress BRCA1/p220 expression.
It is possible that patients with tumors lacking 
BRCA1/p220 expression or function are hit twice. Once 
by losing the powerful tumor suppressor, BRCA1/p220, 
which is involved in DNA-damage repair, cell cycle 
arrest, transcription and chromatin remodeling and a 
second time by gaining the powerful oncogene, BRCA1-
IRIS, which enhances cell proliferation and survival when 
overexpressed. This combined effect, perhaps, contributes 
to increase aggressiveness and drug resistance phenotypes 
in no/low BRCA1/p220 expressing breast tumors, and 
support the view that the two proteins affect a linear 
pathway(s), in which BRCA1/p220 silencing and/or 
BRCA1-IRIS overexpression gives survival advantages to 
cancer cells and promotes the formation of death resistant 
TN/BL breast cancer cells. We therefore propose that 
chemotherapeutical targeting of BRCA1-IRIS might be 
beneficial in eradicating BRCA1/p220-associated or TN/
BL tumors cancer diseases. 
MATERIALS AND METHODS
Cell culture and transfection
Human mammary epithelial cells were cultured in 
MEGM modified medium (Lonza). All other breast cancer 
cell lines used in this study were grown in RPMI-1640 
supplemented with 10% FBS. Small interfering RNA 
(siRNA) targeting BRCA1/p220 and BRCA1-IRIS were 
described earlier [30], whereas BARD1, AUF, pCPB2 
and HuR siRNAs were from Dharmacon. Transfections 
of plasmids with or without siRNAs were done using 
oligofectamine (Invitrogen). Plasmid transfection was 
done using lipofectamine 2000 (Invitrogen). Cells were Oncotarget 2012; 3:  299-313 310 www.impactjournals.com/oncotarget
harvested after transfection at the indicated times.
Establishment of doxycycline-induced BRCA1-
IRIS expression in HME cells
Full-length BRCA1-IRIS cDNAs containing the 
entire 3`-UTR was amplified from HME total RNA using 
primers described earlier [30] was cloned in the pRevTRE 
plasmid (Clontech). pRev-TRE-IRIS was subsequently 
transfected into selected, rtTA-producing HME clones 
followed by selection with 150µg/ml hygromycin B 
(Sigma). Tet-responsive expression of BRCA1-IRIS 
by doxycycline (1-2 µg, Clontech) was monitored by 
using real time RT/PCR and/or by western analysis. The 
authenticity of all constructs used for transfections was 
verified by sequencing. 
Transient infection of BRCA1-IRIS or BRCA1/
p220 cDNA
In some experiments a lentivirus expressing full-
length BRCA1/p220 or BRCA1-IRIS was used to express 
either  protein  in  transient  expression.  Verification  of 
expression was done using western blotting.
Western blot analysis.
Whole-cell lysates were prepared using cell 
sonication [33,34]. Protein lysates were resolved 
by NuPAGE gels (Invitrogen) and transferred onto 
nitrocellulose or PVDF membranes. Antibodies used 
to detect BRCA1-IRIS are mouse monoclonal antibody 
developed in the lab, to detect BRCA1/p220 we use the 
mouse monoclonal antibody SG-11 (Calbiochem, San 
Diego, Calif), AUF1, pCBP2, HuR and β-actin (Sigma), 
AKT1, AKT2, p-(T308/S473)-AKT, survivin and 
p-(S112/136)-BAD (Cell Signaling), rabbit monoclonal 
CK5 (ab75869), CK17 (ab51056), mouse monoclonal 
CDH3 (ab19350), EGFR (ab5368-13) and rabbit 
polyclonal cyclin E (ab93161) all from abcam. Following 
secondary antibody incubations, signals were visualized 
by enhanced chemo-luminescence.
RT/PCR analysis
Total RNA, isolated with Trizol (Gibco, Life 
Technologies) and DNaseI-treated, was routinely used in 
RT-PCR experiments using SuperScript One-Step RT-PCR 
with Platinum Taq (Invitrogen). Routinely, 5 μg of total 
RNA or 10 μg of poly A+ RNA were used as a template in 
each reaction for amplification of ~450bp of BRCA1-IRIS 
RNA (that is, nucleotides 3,744–4,199 of BRCA1-IRIS 
cDNA), ~486bp of BRCA1/p220 RNA (that is, nucleotides 
4,674–5,160 of BRCA1 cDNA) or ~350bp of GAPDH 
RNA, according to the manufacturer’s instructions. 
Primers to amplify CK5, CK17, CDH3, EGFR and cyclin 
E mRNAs are shown in Supplemental Table 1. 
mRNA stability
For mRNA half-life assessments, three independent 
experiments were performed. Actinomycin D (5µg/
ml) was added and total RNA was prepared at the 
times indicated; mRNA half-lives were calculated after 
quantifying by RT/qPCR, normalizing to 18S RNA levels 
(using a 1:20 dilution of the stock sample), plotting on 
logarithmic scales using GraphPad Prism, and calculating 
the time period required for a given transcript to undergo a 
reduction to one-half of its initial abundance (at time zero, 
before adding actinomycin D) using non-linear regression 
analysis. Comparisons of treatment outcomes were tested 
for statistical differences using the Student t-test for paired 
data. Statistical significance was assumed at a p-value of 
≤ 0.05.
Immunoprecipitation of RNP complexes 
Immunoprecipitation (IP) of AUF1, pCBP2 or HuR 
and BRCA1-IRIS mRNA complexes from HME cell lysates 
was used to assess the association of the endogenous 
proteins with endogenous BRCA1-IRIS mRNA. The IP 
assay was performed essentially as described earlier [33]. 
Following Immunoprecipitation, extensive washes and 
digestion of proteins in the IP material [33], the RNA 
was extracted and used to perform reverse transcription 
(RT) followed by PCR to detect the presence of BRCA1-
IRIS mRNA using gene-specific primer pairs described in 
[30]. GAPDH mRNA was used to normalize the data. We 
routinely normalized the results by measuring in parallel 
the binding of BRCA1-IRIS mRNA to IgG and to anti-
AUF1, pCBP2 or HuR antibodies [33]. 
Luciferase analysis
A 210bp representing the entire 3`-UTR of BRCA1-
IRIS or the 3`-UTR of c-fos [30,50,51] were subcloned 
into the HpaI site of the Rous sarcoma virus-luciferase 
(RSV-Luc) expression vector. A plasmid encoding RSV-
β-galactosidase (RSV-β-Gal; ATCC) was co-transfected 
as an internal control. In other experiments, fragments 
(~1-3kb) containing human AUF1, pCBP2, CK5, EGFR, 
CycD1  or  GADD45 genes promoter elements were 
generated by PCR amplification from human genomic 
DNA (G304A, Promega). Each promoter fragment was 
cloned upstream of the firefly luciferase reporter gene 
in the pGL3-Basic vector (Promega) using the protocol 
described in Chock et al., 2010a. The resultant plasmids 
were designated as pGL3-AUF1, -pCBP2, -GADD45, 
-CK5, -EGFR and –CycD1. Comparisons of treatment Oncotarget 2012; 3:  299-313 311 www.impactjournals.com/oncotarget
outcomes were tested for statistical differences using the 
Student t-test for paired data. Statistical significance was 
assumed at a P-value of ≤ 0.05. 
Active Caspase 3/7 detection and MTS assays
The Apo-ONE® Homogeneous Caspase-3/7 kit 
and CellTiter 96® Aqueous Non-Radioactive Cell 
Proliferation Assay kit were used according to supplier 
(Promega) protocol. Comparisons of treatment outcomes 
were tested for statistical differences using the Student 
t-test for paired data. Statistical significance was assumed 
at a p-value of ≤ 0.05.
Chromatin immunoprecipitation (ChIP) analysis
ChIP was performed as described in [30]. PCR 
conditions are as follows; 10min at 94°C to activate the 
Taq polymerase followed by 30 cycles of denaturation 
for 1min at 94°C, annealing for 1min at 60°C, elongation 
for 1min at 72°C and a final extension for 7min at 72°C. 
Primers to amplify the immediate promoter regions or a 
regions located ~10kb upstream of CK5, CK17, CDH3, 
EGFR and cyclin E are shown in Supplemental Table 1.  
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